Open Study to Investigate Pancreatic Islet Mass by Positron Emission Tomography Using the Tracer [11C]5-hydroxytryptophane

Uppsala University Hospital1 site in 1 country20 target enrollmentMarch 2012

ConditionsType 1 Diabetes

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type 1 Diabetes
Sponsor: Uppsala University Hospital
Enrollment: 20
Locations: 1
Primary Endpoint: Difference in pancreatic uptake of % injected dose (ID) [11]5-hydroxy tryptophan between healthy volunteers and patients with long-standing type 1 diabetes
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study investigates the hypothesis that differences in beta-cell mass in patients with diabetes and healthy individuals can be monitored by the positron emission tomography (PET) tracer [11C]5-hydroxytryptophane.

Registry

clinicaltrials.gov

Start Date

March 2012

End Date

March 2013

Last Updated

12 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Uppsala University Hospital

Responsible Party

Principal Investigator

Per-Ola Carlsson

Professor

Uppsala University Hospital

Eligibility Criteria

Inclusion Criteria

•Adult patients with type 1 diabetes
•Adult, healthy controls

Exclusion Criteria

•Pregnancy
•Impaired renal function

Outcomes

Primary Outcomes

Difference in pancreatic uptake of % injected dose (ID) [11]5-hydroxy tryptophan between healthy volunteers and patients with long-standing type 1 diabetes

Time Frame: To be measured at Positron emission tomography investigation for all study persons.